Stock Track | Hims & Hers Health Soars 10.33% in After-Hours Trading on Regulatory Easing for Peptides and Novo Nordisk Partnership

Stock Track

Apr 16

Hims & Hers Health Inc. (HIMS) experienced a significant surge of 10.33% in after-hours trading on Wednesday, extending gains from a strong intraday session.

The sharp rise appears driven by two major catalysts. First, U.S. Health Secretary Robert F. Kennedy Jr. signaled that federal regulators plan to loosen rules on peptide treatments. The Food and Drug Administration is moving forward with a plan to reassess popular peptides and has scheduled meetings to discuss easing restrictions, which would make these treatments more widely available. Hims & Hers had previously indicated to investors its interest in entering the peptide space, making this regulatory shift a positive development for its future business categories.

Secondly, the company is set to announce a new collaboration agreement with pharmaceutical giant Novo Nordisk. The partnership will authorize the sale of Novo Nordisk's weight-loss drugs on the Hims platform, marking a significant commercial milestone and expanding Hims' offerings in the high-demand weight management market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1123253293"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123253293\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123253293?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 08:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123253293","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 10.33% in After-Hours Trading on Regulatory Easing for Peptides and Novo Nordisk Partnership","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) experienced a significant surge of 10.33% in after-hours trading on Wednesday, extending gains from a strong intraday session.</p><p>The sharp rise appears driven by two major catalysts. First, U.S. Health Secretary Robert F. Kennedy Jr. signaled that federal regulators plan to loosen rules on peptide treatments. The Food and Drug Administration is moving forward with a plan to reassess popular peptides and has scheduled meetings to discuss easing restrictions, which would make these treatments more widely available. Hims & Hers had previously indicated to investors its interest in entering the peptide space, making this regulatory shift a positive development for its future business categories.</p><p>Secondly, the company is set to announce a new collaboration agreement with pharmaceutical giant Novo Nordisk. The partnership will authorize the sale of Novo Nordisk's weight-loss drugs on the Hims platform, marking a significant commercial milestone and expanding Hims' offerings in the high-demand weight management market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 10.33% in After-Hours Trading on Regulatory Easing for Peptides and Novo Nordisk Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 10.33% in After-Hours Trading on Regulatory Easing for Peptides and Novo Nordisk Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-16 08:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) experienced a significant surge of 10.33% in after-hours trading on Wednesday, extending gains from a strong intraday session.</p><p>The sharp rise appears driven by two major catalysts. First, U.S. Health Secretary Robert F. Kennedy Jr. signaled that federal regulators plan to loosen rules on peptide treatments. The Food and Drug Administration is moving forward with a plan to reassess popular peptides and has scheduled meetings to discuss easing restrictions, which would make these treatments more widely available. Hims & Hers had previously indicated to investors its interest in entering the peptide space, making this regulatory shift a positive development for its future business categories.</p><p>Secondly, the company is set to announce a new collaboration agreement with pharmaceutical giant Novo Nordisk. The partnership will authorize the sale of Novo Nordisk's weight-loss drugs on the Hims platform, marking a significant commercial milestone and expanding Hims' offerings in the high-demand weight management market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1123253293","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123253293","pubTimestamp":1776297854,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) experienced a significant surge of 10.33% in after-hours trading on Wednesday, extending gains from a strong intraday session.The sharp rise appears driven by two major...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health盘后大涨10.33%，因多肽监管放松和诺和诺德合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a significant surge of 10.33% in after-hours trading on Wednesday, extending gains from a strong intraday session.The sharp rise appears driven by two major catalysts. First, U.S. Health Secretary Robert F. Kennedy Jr. signaled that federal regulators plan to loosen rules on peptide treatments. The Food and Drug Administration is moving forward with a plan to reassess popular peptides and has scheduled meetings to discuss easing restrictions, which would make these treatments more widely available. Hims & Hers had previously indicated to investors its interest in entering the peptide space, making this regulatory shift a positive development for its future business categories.Secondly, the company is set to announce a new collaboration agreement with pharmaceutical giant Novo Nordisk. The partnership will authorize the sale of Novo Nordisk's weight-loss drugs on the Hims platform, marking a significant commercial milestone and expanding Hims' offerings in the high-demand weight management market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}